Advances in the Treatment of HIV: Focus on Newer Strategies

In this presentation, Dr. Andrew Zolopa, Professor Emeritus of Medicine at Stanford School of Medicine, discusses the history of antiretroviral therapy (ART) in HIV-infected patients. He highlights some of the potential long-term risks of ART regimens in this patient population. Dr. Zolopa describes the recent advances in the treatment of HIV-infected patients, such as two-drug regimens which have been included in clinical guidelines, and long-acting injectable drugs that are being evaluated in clinical trials.

In the second part of his presentation, Dr. Zolopa examines the different strategies and challenges of treating viral suppressed HIV-infected patients versus treatment-naïve patients. 

CME Information

CME Credit Available

You may claim CME credit after watching this activity.

Needs Statement

Faculty and trainees within the Department of Medicine who are involved in the care of patients need to be regularly updated with the recent advances and guidelines in the fields of medicine and quality improvement to increase clinical knowledge. This Grand Rounds series also aims to provide learners with the appropriate skills to implement the advances and guidelines in clinical practice to enhance the quality of patient care and outcomes.

Objectives

At the conclusion of this activity, the participant should be able to:

  • Review the history of antiretroviral therapy (ART) development, highlighting successes and challenges.
  • Discuss the risk of long-term toxicities in patients treated with ART.
  • Analyze the latest advances in the treatment of HIV-infected patients with a focus on newer strategies for managing those patients over the long term.

Target Audience

  • Physicians
  • Medical Students
  • Fellows
  • Residents
  • Nurses
  • Other Health Professionals

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Director

Richard J. Hamill, M.D.
Professor
Department of Medicine
Baylor College of Medicine
Houston, Texas
Disclosure: Nothing to disclose.

Term of Approval

August 1, 2019 through August 31, 2021. Original release date: August 1, 2019.

Disclosure Policy

The Office of Continuing Medical Education (OCME) makes every effort to develop CME activities that are scientifically based, accurate, current, and objectively presented. In accordance with the Accreditation Council for Continuing Medical Education Standards for Commercial SupportSM, Baylor College of Medicine (BCM) has implemented a mechanism requiring everyone in a position to control the content of an educational activity (e.g., directors, planning committee members, contributors, peer reviewers) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships: 1) at the time of the activity or within 12 months prior; and 2) of their spouses/partners.

Baylor College of Medicine does not view the existence of interests or relationships with commercial entities as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.

If at any time during this activity you feel that there has been commercial or promotional bias, please inform us by using the commercial bias comments box in the evaluation form. Please answer the questions about balance in the CME activity evaluation candidly.

Disclosures

The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:

Presenter

  1. Andrew Zolopa, M.D.

    Andrew Zolopa, M.D.

    Professor Emeritus
    Stanford University School of Medicine

    Disclosure:

    Nothing to disclose.